‘Will burst crackers after 10 pm’: BJP MP vows to violate SC order

New Delhi, May 25: The pending class 10 and 12 board exams will be conducted by CBSE at 15,000 centres across the country instead of 3,000 centres planned earlier, Union HRD Minister Ramesh Pokhriyal 'Nishank' announced on Monday.

The exams, which were postponed due to a nationwide lockdown imposed on March 25 to contain the spread of COVID-19, will now be held from July 1 to 15.

"The class 10, 12 exams will now be conducted at over 15,000 exam centres across India. Earlier, CBSE was slated to hold exams at only 3,000 centres," Nishank said.

The decision has been taken to ensure social distancing at exam centres and minimise travel for students.

The HRD ministry has already announced that students will appear for exams at schools in which they are enrolled rather than external examination centres.

According to home ministry guidelines, there will be no exam centre in COVID-19 containment zones and states will be responsible for making transport arrangements for students to reach their respective centres.

Usually, board examinations are held at designated test centres to ensure minimum bias from schools and enable independent external invigilators to monitor the examination process.

While Class 12 exams will be conducted across the country, the Class 10 exams are only pending in North East Delhi, where they could not be held due to the law-and-order situation in the wake of protests against the amended citizenship act.

The CBSE class 10 and 12 board exam evaluation is being carried out from home.

The HRD ministry had earmarked 3,000 evaluation centres from where answer sheets would be distributed to teachers at their homes for evaluation and then collected.

Universities and schools across the country have been closed since March 16 when the Centre announced a countrywide classroom shutdown as one of the measures to contain the COVID-19 outbreak.

Later, a 21-day nationwide lockdown was announced on March 24, which came into effect the next day. It has now been extended till May 31. The board was not able to conduct class 10 and 12 exams on eight examination days due to the coronavirus outbreak.

Due to the law-and-order situation in North East Delhi, CBSE was not able to conduct exams on four examination days, while a very small number of students from and around this district were not able to appear in exams on six days.

The board had last month announced that it will only conduct pending exams in 29 subjects which are crucial for promotion and admission to higher educational institutions.

The modalities of assessment for the subjects for which exams are not being conducted will be announced soon by the board.

The schedule has been decided in order to ensure that the board exams are completed before competitive examinations such as engineering entrance JEE-Mains, which is scheduled from July 18-23 and medical entrance exam NEET that will be held on July 26.

Ujjain, Jul 9: Kanpur encounter main accused Vikas Dubey has been arrested at a police station here on Thursday, as per sources in the Uttar Pradesh government.

"Vikas Dubey, the main accused in Kanpur encounter case, has been arrested at a police station in Ujjain," said UP government sources.

Dubey is the main accused in the encounter that took place in Kanpur last week, in which a group of assailants allegedly opened fire on a police team, which had gone to arrest him.

Eight police personnel were killed in the encounter.

Earlier today, Bahua Dubey and Prabhat Mishra, close aides of the main accused, were killed in separate encounters in Etawah and Kanpur respectively.

Whereas, Shyamu Bajpai, also an aide to Dubey, has been arrested by Chaubeypur police following an encounter. He carried a reward of Rs 25,000. Uttar Pradesh's Special Task Force (STF) had gunned down Vikas Dubey's close aide Amar Dubey in Hamirpur district, earlier on Wednesday.

New Delhi, Jun 25: After the Drug Controller General of India (DCGI) given its approval to manufacture and market the generic version of COVID-19 drug Remdesivir, COVIFOR, Hyderabad-based drugmaker Hetero Limited has delivered the first set of 20,000 vials in two equal lots of 10,000 each across 5 states.

The first batch, which is being marketed under the brand name of COVIFOR, was delivered to Maharashtra, Delhi, Gujarat Tamil Nadu and Hyderabad. Hetero has set a target to produce one lakh vials of the drug in two-three weeks.

The other lot would be supplied to Kolkata, Indore, Bhopal, Lucknow, Patna, Bhubaneshwar, Ranchi, Vijayawada, Cochin, Trivandrum and Goa within a week to meet the emergency requirements.

Managing director of Hetero Healthcare M Srinivasa Reddy said “the launch of Covifor in the country is a milestone in addressing public health emergencies. Through Covifor, we hope to reduce the treatment time of a patient in a hospital thereby reducing the increasing pressure on the medical infrastructure overburdened ue to accelerating COVID-19 infection rates," he said as reported by news agency.

"We are closely working with the government and the medical community to make Covifor quickly accessible to both public and private healthcare settings across the country”, Reddy said.

Covifor is a generic brand of Remdesivir which is used for the treatment of COVID-19 in adults and children hospitalised with strong symptoms of the disease. The Health Ministry had, on June 13, recommended the use of anti-viral drug Remdesivir in moderate stage of COVID-19.

Dr Reddys Laboratories and Hetero are among others which have separately entered into non-exclusive licensing agreements with the original drug-maker Gilead Sciences Inc to register, make and sell the investigational drug Remdesivir in India and other countries.

Remdesivir would be made in the company's formulation facility in Hyderabad, which has been approved by global regulatory authorities such as US Food and Drug Administration (USFDA) and EU, among others, Hetero had earlier said.

The treatment first showed improvement in trials on coronavirus patients and was approved for emergency use in severely ill patients in the United States and South Korea.